Effects of zibotentan and dapagliflozin combined in patients with compensated cirrhosis: A randomized placebo-controlled exploratory study.

Saved in:
Bibliographic Details
Title: Effects of zibotentan and dapagliflozin combined in patients with compensated cirrhosis: A randomized placebo-controlled exploratory study.
Authors: Garcia-Pagan JC; Barcelona Hepatic Hemodynamic Laboratory, Liver Unit, Hospital Clínic, Institut de Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS). CIBEREHD (Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas). Health Care Provider of the European Reference Network on Rare Liver Disorders (ERN RARE-Liver). Departament de Medicina i Ciències de la Salut. Universitat de Barcelona, Barcelona, Spain., Gluud LL; Gastro Unit, Copenhagen University Hospital Hvidovre and Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Mandorfer M; Vienna Hepatic Hemodynamic Lab, Division of Gastroenterology and Hepatology, Department of Medicine III, Medical University of Vienna, Vienna, Austria., Schattenberg JM; Department of Internal Medicine II, Saarland University Medical Center, Homburg, Germany., De Gottardi A; Gastroenterology and Hepatology, Luzerner Kantonsspital, Luzern, Switzerland., Berzigotti A; Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Fortea JI; Gastroenterology and Hepatology Department, Clinical and Translational Research in Digestive Diseases, Valdecilla Research Institute (IDIVAL), Marqués de Valdecilla University Hospital, Santander, Spain., Martínez AA; Dept of Gastroenterology, Hospital Universitario Ramon y Cajal, IRYCIS, CIBEREHD, University of Alcala, Madrid, Spain., Alvarado-Tapias E; Department of Gastroenterology, Hospital Santa Creu i Sant Pau, Barcelona, Spain. Centre for Biomedical Research in Liver and Digestive Diseases Network (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain. Universitat Autònoma de Barcelona (UAB), Departament de Medicina UAB, Barcelona, Spain., Berning M; Department of Medicine I, University Hospital Dresden, Technische Universität Dresden (TU Dresden), Dresden, Germany., Petryszyn P; Late-stage Clinical Development, Cardiovascular, Renal and Metabolic, AstraZeneca, Warsaw, Poland.; Department of Clinical Pharmacology, Wroclaw Medical University, Wroclaw, Poland., Henricson E; Biopharmaceutical Clinical Operations, Cardiovascular, Renal and Metabolic, AstraZeneca, Gothenburg, Sweden., Berglind N; Late-stage Clinical Development, Cardiovascular, Renal and Metabolic, AstraZeneca, Gothenburg, Sweden., Lin M; Late-stage Development, Biometrics, Cardiovascular, Renal and Metabolic, AstraZeneca, Gaithersburg, Maryland, USA., Persson K; Late-stage Clinical Development, Cardiovascular, Renal and Metabolic, AstraZeneca, Gothenburg, Sweden., Mercier AK; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Gothenburg, Sweden., Ambery P; Late-stage Clinical Development, Cardiovascular, Renal and Metabolic, AstraZeneca, Gothenburg, Sweden., Bosch J; Department of Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland., Oscarsson J; Late-stage Clinical Development, Cardiovascular, Renal and Metabolic, AstraZeneca, Gothenburg, Sweden., Rockey DC; Medical University of South Carolina, College of Medicine, South Carolina, USA.
Source: British journal of clinical pharmacology [Br J Clin Pharmacol] 2026 May; Vol. 92 (5), pp. 1326-1338. Date of Electronic Publication: 2025 Dec 08.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II; Multicenter Study
Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 7503323 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1365-2125 (Electronic) Linking ISSN: 03065251 NLM ISO Abbreviation: Br J Clin Pharmacol Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1365-2125
DOI:10.1002/bcp.70332